COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.

Slides:



Advertisements
Similar presentations
Implementing a TB-Control Program in Prisons: The Basics Dr. Mayra Arias.
Advertisements

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Unit 1. Introduction TB Infection Control Training for Managers at the National and Subnational Levels.
MDR-TB GLOBALLY AND IN THE REGION 2013 Dr Samiha Baghdadi Medical officer – STB WHO – EMRO Cairo March 2014.
Improving diagnosis TB laboratory strengthening.
Ram Deo Chaudhary Programme Manager, BNMT. Outlines VMGO of BNMT Guiding principles of partnership Historical background Current efforts Strengths Area.
1 [INSERT COUNTRY NAME HERE] Introduction to the National MDR-TB Control Strategy SESSION 1 Insert country/ministry logo here.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
INFECTION CONTROL MEASURES DOTS PLUS STRATEGY LRS Institute of Tuberculosis & Respiratory Diseases Sri Aurobindo Marg, New Delhi
World TB Day 2011 March 24, 2011 Mavuso Centre Manzini – Kingdom of Swaziland.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Accelerating PMDT scale up in Ethiopia
GUIDELINES & TOOLS for HOSPITAL DOTS LINKAGE (HDL)
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
Module 1: Course Overview. Course Objectives Teach you everything you need to know about the TB Program Describe TB the roles and responsibilities of.
TUBERCULOSIS CONTROL Experience of Guyana Dr Jeetendra Mohanlall
National TB/ Leprosy Programme Manager
experience from Lesotho
Accelerating TB/HIV activities in Zambia Alwyn Mwinga 2007 HIV Implementers Meeting 20 June 2007.
Nationwide scale-up of TB/HIV collaborative activities in Ethiopia Yibeltal Assefa, MD, MSc Head, Health programs Department TB/HIV core group Addis Ababa.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
World Health Organization
Framework and Standards for Effective TB Control Module 3 – March 2010
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Downloaded from Accelerate scaling up of TB/HIV activities in Tanzania Dr. N.G.SIMKOKO WHO/NTLP - Tanzania.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
“World TB day and TB in Mongolia”
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
Guidance on TB infection control Fabio Scano Stop TB, WHO.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.
Project Goals  Support the National Tb Program (NTP)  Developed National Guidelines for prevention and control of Tb  Developed guidelines for treating.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
June 30, 2010 TB Program Thailand MOPH – U.S. CDC Collaboration TB Project Implementation: Impact on NTP?
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Implementation of Collaborative TB/HIV Activities by ICAP: Success and Challenges Andrea Howard, M.D., M.S. 14 th Core Group Meeting of TB/HIV Working.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB, MDR-TB and XDR-TB in South Africa October 2006.
Public Health. TB-DOTS program Government commitment Case detection by DSSM among symptomatic patients self-reporting to health services Standard short-course.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 7: GAP BETWEEN AVAILABILTY OF DRUG SUSCEPTIBILITY.
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
TB infection control and prevention of XDR Group II.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Intensified TB case finding and infection control in Tanzania – opportunities and challenges Denis Tindyebwa Technical Director EGPAF Tanzania.
TB and HIV integrated services at Martin Preuss Centre in Lilongwe, Malawi : “The Lighthouse Trust initiative” Dr Sam Phiri Executive Director Lighthouse.
11 Laboratory Quality Improvement for clinical HIV/AIDS Services in the Uniformed Forces Mwaibako, J, Shija, L; Haverkamp, G; van den Hombergh; Katebalila,
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Strengthening TB and HIV&AIDS Responses in East Central Uganda Strengthening Laboratory TB diagnostic capacity of peripheral laboratories in East Central.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
TB- HIV Collaborative activities in Romania- may 2006 status
This is an archived document.
TB/HIV surveillance : Who is going to get the job done?
Update on SBCC Activities of Challenge TB Bangladesh
Implementing a TB-Control Program in Prisons: The Basics
5th DEWG meeting Conclusions
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
South Africa: From ProTest to Nationwide Implementation
From ProTEST to Nationwide Implementation
The STOP TB Strategy – 2009 VISION: A TB-free world
Presentation transcript:

COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU SHONGWE SWAZILAND NATIONAL TUBERCULOSIS CONTROL PROGRAMME

PRESENTATION OUTLINE  TB SITUATION IN SWAZILAND  COUNTRY RESPONSE TO M(X) DR TB  CHALLENGES

Country situation  Swaziland has a population of about 1.1 million with an area of Km².  The country is divided into 4 regions which are Hhohho, Lubombo, Shiselweni and Manzini.  According to the WHO Global TB Report of 2008, the incidence rate of TB in Swaziland is the highest in the world OF 1155 PER 100,000 population.  The TB programme faces problems of poor diagnosis of cases, poor case holding and high defaulter rates.  The treatment success for new pulmonary smear positive was 42% while that for all cases (new and retreatment) was 34%.  In 2007, 9636 of TB cases were notified.  79.6% of TB patients are co-infected with HIV

Country efforts to control TB: focus(1)  improving the quantity and quality of staff involved in TB control;  increasing TB case detection and treatment success rates with expanded DOTS coverage at national and lower levels;  scaling up access to counseling and testing for HIV among TB patients  scaling up interventions to manage TB and HIV together, including increased access to anti-retroviral therapy for TB patients who are co-infected with HIV;  Increase investment in laboratory infrastructures to enable better detection and management of resistant cases.

Swaziland Experience and Response: The Emergency Plan MDR/XDR-TB Task force was formed after XDR-TB was diagnosed in 2006 The Task force developed an Emergency MDR/XDR response plan in 2006 and the Objectives of the emergency response plan for drug resistant TB were:  To Conduct a rapid survey of drug-resistant TB to establish whether Swaziland has cases of Extreme Multi drug Resistant TB;  To build capacity of a critical mass of clinicians, Nurses and TB programme staff to effectively respond to M(X)DR-TB;  To Strengthen and expand current national TB laboratory capacity to deal with diagnosis for drug resistant TB;  To develop comprehensive DR-TB guidelines that incorporate collaborative TB/HIV activities  To Declare tuberculosis a national disaster.

Swaziland Experience and Response: Priority activities 1. Establishment of a case management plan for patients suspected of M(X) DR, once identified. identification of a facility where these patients would be admitted/Isolated: a TB hospital has been built for this purpose ensure the availability of N 95 masks to protect health workers from the infection: N95 masks were procured and health care workers trained on their use; Fast-track drug susceptibility testing for 1st and 2nd-line anti-TB drugs for such suspects; DST capacity at the NRL was developed for first line DST and collaboration established with SA MRC for second line DST

Swaziland Experience and Response: Develop MDR-TB guidelines 2. Develop technical guidelines and train health workers on suspicion, management, follow up and discharge of Mdr/Xdr TB: Draft Drug Resistant TB guidelines are under finalization; 60 nurses and 45 doctors have been trained on MDR-TB in Implement case finding strategies for MDR-TB and expand the availability and use of culture and DST for:  Contacts of known MDR(X)TB patients, including health care workers;  All patients being retreated for TB;  All patients with sputum results remaining smear- positive at 2-3 months;  All patients failing to improve clinically;

Swaziland Experience and Response: Training on XDR/MDR-TB 4. Identify and build a data base on all MDR-TB that are currently under treatment in Swaziland, who are potential of developing XDR and could be promoting ongoing transmission; Printing of MDR-TB registers, treatment and patient cards has been done. Currently 98 MDR-TB patients are on treatment. 5. Conduct a rapid survey of drug-resistant TB: rapid survey on XDR-TB was conducted July-Aug 2007 using standardized protocols developed by WHO, CDC, SAMRC and URC to assess the presence of M(X) DR-TB in among high risk patients and contacts. 4 XDR-TB patients were identified. 2 died before initiation of therapy and the other 2 are still on treatment and doing well 6. Conduct BCC and IEC activities to enhance M(X)DR TB identification and management: Flyers and other IEC materials have been developed

Swaziland Experience and Response 7. Ensure strict control and proper use of first- and second-line anti-TB drugs by following WHO Guidelines in an effort to prevent emergence of further drug resistance: drug management focal person was appointed in the NTP in June  Health care workers were trained on management of TB pharmaceuticals and supplies in May Apply to the Green Light Committee for access to quality second-line drugs :Application submitted in September 2008

Swaziland Experience and Response: strengthen lab capacity 9. Strengthen and expand current national TB laboratory capacity: Strengthening all aspects of TB laboratory processes,-. specimen collection and transport, smear microscopy, culture, drug susceptibility testing (DST), and information management; Establish linkages with a supra national laboratory to harness capacity for rapid detection resistance to first second-line anti-TB drugs, and proficiency testing for first line drugs DST; MRC sends quarterly DST panels Implement quality control and quality assurance of the TB laboratory network according to international guidelines; NICD has been contracted to support QA Fast-track hiring and training of laboratory personnel to increase capacity for microscopy, cultures and DST and technical oversight: 2 lab technicians, 6 microscopists employed

Swaziland Experience and Response: Infection Control 9. Implement appropriate infection control precautions in health care facilities, with special emphasis on those facilities providing care for people living with HIV/AIDS: Develop and implement appropriate institution-level infection control plans consisting of: Administrative control measures  Environmental control measures; respiratory personal protection equipment: N95 Draft infection control guidelines have been developed. A senior nurse attended a 3 day International training on Infection control in Botswana in November 2007 and was expected to conduct the in-country training

Swaziland Experience and Response: MDR-TB and collaborative TB/HIV activities 10. Implement TB/HIV collaborative activities:  Provide HIV testing for all TB patients including MDR-TB patients: Ongoing  Provide ART to eligible TB HIV positive patients including MDR-TB patients: ongoing  Provide cotrimoxazole for all HIV positive patients including MDR-TB patients: ongoing

Challenges Inadequate follow up and support mechanisms for patients on MDR-TB treatment Inadequate contact tracing mechanisms for contacts of MDR- TB patients No protocols for doing cultures for the MDR TB and XDRTB suspects Lack of capacity (human resource capacity) Human resource: Numbers and skills and knowledge on XDRTB No monitoring and reporting tool to the programme (surveillance system) Pill burden creates high default rates and increase occurrence of side effects Referral system between the two programmes is weak (collaborative TB/HIV at facility level still a challenge) Health workers not utilizing N95 masks TB has not been declared national disaster